

Human VEGF-A Monoclonal Antibody, Endotoxin 0.05 EU/mg

Catalog No.: YR0136

Basic Information

Molecular Weight

150 kDa

Endotoxin

<0.05EU/mg (<0.00005EU/μg)

Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Brolucizumab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Human VEGF-A

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 7.4

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)